[Efficiency of rituximab in acquired hemophilia: report of two cases and review of literature].
BACKGROUND
Acquired hemophilia due to an inhibitor of factor VIII is a rare clinical situation.


METHODS
Rituximab is now used in the treatment of acquired hemophilia. We report two cases of acquired hemophilia treated by rituximab with efficiency.


CONCLUSIONS
Rituximab appears to be a first line immunosuppressive therapy in acquired hemophilia, especially in post-partum hemophilia.
Millet
A
A
Service de médecine interne, département de médecine de l'adulte, hôpital Sud, 16, boulevard de Bulgarie, 35203 Rennes cedex 02, France.
Decaux
O
O
Bareau
B
B
Guillet
B
B
Cazalets
C
C
Perlat
A
A
Jego
P
P
Grosbois
B
B
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005169:Factor VIII / Q000378:metabolism; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D005169:Factor VIII